Evaluation of Effectiveness and Safety of an ICU Insulin Infusion Protocol
Objective. To evaluate the efficacy, safety, and clinical outcomes of, and protocol deviations with the use of the Modified Yale Insulin Infusion Protocol (IIP) compared to usual/standard care in the local setting.
Methods. Chart review of patients admitted in two ICUs over a 2-year period was done. Patients eligible for intensive glycemic control were identified. Efficacy, safety and clinical outcomes were compared between the Modified Yale IIP and usual/standard care. Charts managed with the IIP were appraised for protocol deviations.
Results. Eighty-one patients met the inclusion criteria and 34.6% used the IIP. The IIP group achieved a lower mean blood glucose (185.1 vs 212.1 mg/dl, p<0.05). They reached normoglycemia (5 vs 12 hours, p<0.05) and target range of 140-180 mg/dl (8.3 vs 18.3 hours, p<0.05) earlier. Hypoglycemia was rare (median 0%) in both groups. No difference in mortality or morbidity was seen. Hospital (13.9 vs 8.1 days, p<0.05) and ICU stay (5.5 vs 3.0 days, p<0.05) were longer in the IIP group. A mean of 11 deviations per patient occurred, the majority of which were errors on insulin dose administered (66.6%).
Conclusion. The Modified Yale IIP is efficaceous, safe and yielded better glycemic profiles than usual care. Majority of protocol deviations were on the insulin dose administered
Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: A systematic overview. Lancet. 2000;355:773–778.
Cheung NW, Wong VW, McLean M. The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: A randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care. 2006;29:765–770.
Svensson AM, McGuire DK, Abrahamsson P, Dellborg M. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J. 2005;26:1255–1261.
Kosiborod M, Rathore SS, Inzucchi SE, et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: Implications for patients with and without recognized diabetes. Circulation. 2005;111:3078–3086.
Fogelholm R, Murros K., Rissanen A, Avikainen S. Admission blood glucose and short term survival in primary intracerebral haemorrhage: A population based study. J Neurol Neurosurg Psychiatry 2005;76:349–353.
Ata A, Lee J, Bestle SL, Desemone J, Stain SC. Postoperative hyperglycemia and surgical site infection in general surgery patients. Arch Surg. 2010;145(9):858-864.
Yendamuri S, Fulda GF, Tinkoff GH. Admission hyperglycemia as a prognostic indicator in trauma. J Trauma. 2003;55:33–38
Furnary AP, Wu Y, Bookin SO. Effect of hyperglycemia and continuous intravenous insulin infusions on outcomes of cardiac surgical procedures: The Portland Diabetic Project. Endocr Pract. 2004;10(suppl 2):21–33.
American Diabetes Association. Standards of Medical Care in Diabetes—2011. American Diabetes Association Position Statement. Diabetes Care. January 2011; 34(Supp 1):S11-S16.
Goldberg PA, Siegel MD, Sherwin RS, et al. Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. Diabetes Care. 2004;27:461–467.
Josol CV, Cardino MJ, Jimeno CA, Isip-Tan IT. Efficacy and safety of the UP-PGH endocrine insulin infusion protocol in controlling hyperglycemia in UP-PGH Medical Intensive Care Unit and Central Intensive Care Unit. 2006 (unpublished).
Department of Medicine, University of the Philippines-Philippine General Hospital Medical Intensive Care Unit Annual Census. 2010 (unpublished).
Department of Medicine, University of the Philippines-Philippine General Hospital Central Intensive Care Unit Annual Census. 2010 (unpublished).
Chiavone PA, Sens YA. Evaluation of APACHE II System among Intensive Care patients at a teaching hospital. Sao Paulo Me J. 2003 Mar 5; 121 (2):53-7.
Tamaki M, Shimizu T, Kanazawa A, et al. Efficacy and safety of modified Yale insulin infusion protocol in Japanese diabetic patients after open-heart surgery. Diabetes Res Clin Pract. 2008 Sep;81(3):296-302.
Oliveira S. Yale insulin protocol infusion in sepsis patients. Critical Care. 2011;15(Suppl 3):P5.
Bolton M, Richard A, Blonde L, Burshell A. Effective glycemic management in hospitalized patients: A multidisciplinary approach. Ochsner J. 2007; 7(2):52-7.
Diener JRC, Dos Prazeres CEE, D Rosa CM, Alberton UC, Ramos CCS. Assessment of effectiveness and safety of Yale insulin infusion protocol in a Brazilian Medical and Surgical Intensive Care Unit. Revista Brasileira de Terapia Intensiva. 2006;18(3):268-275.
Ngalob QG, Jimeno CA, Isip-Tan IT., Medical staff experience of an ICU insulin infusion protocol in a tertiary hospital in the Philippines. 2012 (unpublished).
Sauer P, Van Horn ER. Impact of intravenous insulin protocols on hypoglycemia, patient safety, and nursing workload. Dimensions of Critical Care Nursing. 2009; 28(3): 95-101.
Goldberg PA, Inzucchi SE. Selling root canals: Lessons learned from implementing a hospital insulin infusion protocol. Diab Spectr. 2005 January; 18(1):28-33.
Malesker MA, Foral PA, McPhillips AC, Christensen KJ, Chang JA, Hilleman DE. An efficiency evaluation of protocols for tight glycemic control in Intensive Care Units. Am J Crit Care. 2007;16:589-598.
Cyrus RM, Szumita PM, Greenwood BC, Pendergrass ML. Evaluation of compliance with a paper-based, multiplication-factor, intravenous insulin protocol. Ann Pharmacother. 2009 Sep;43(9):1413-8.
Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc. 2004 Aug;79(8):992-1000.
Arabi Y, Venkatesh S, Haddad S, Shimemeri AA, Malik SA. A prospective study of prolonged stay in the intensive care unit: Predictors and impact on resource utilization. Int J Qual Health Care.2002; 14 (5):403-410.
Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European Intensive Care Units: Results of the SOAP study. Crit Care Med. 2006; 34:344–353.
Journal of the ASEAN Federation of Endocrine Societies is licensed under a Creative Commons Attribution-NonCommercial 4.0 International. (full license at this link: http://creativecommons.org/licenses/by-nc/3.0/legalcode).
To obtain permission to translate/reproduce or download articles or use images FOR COMMERCIAL REUSE/BUSINESS PURPOSES from the Journal of the ASEAN Federation of Endocrine Societies, kindly fill in the Permission Request for Use of Copyrighted Material and return as PDF file to email@example.com or firstname.lastname@example.org.
A written agreement shall be emailed to the requester should permission be granted.